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ORIGINAL ARTICLE
Hemophilia B, also termed as Christmas disease,1
is a congenital X-linked recessive disorder caused
by a variety of defects in the factor IX (FIX) gene,2,3
resulting in a deficiency or dysfunction of the
procoagulant protein, plasma FIX.4 Abnormal
bleeding, especially to joints and soft tissues,
characterizes the clinical manifestations of such
patients and the severity of symptoms is related
to the baseline level of FIX activity.
cReplacement therapy, including prophylacti
rand on-demand treatment, with FIX products fo
tpatients with hemophilia B can correct the defec
ttemporarily and lead to improvements in join
function and quality of life for them.5 In the past,
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replacement therapy was given by intravenous de-
livery of plasma FIX, initially fresh-frozen plasma,
then prothrombin complex concentrates (PCCs),
and recently human plasma-derived purified FIX
(pdFIX) concentrates.6 These FIX plasma products
have been specifically treated to reduce the possible
transmission of human pathogenic viruses, such as
hepatitis viruses, human immunodeficiency virus,
and parvovirus. However, the risk of viral infec-
tivity from these products has not been totally elimi-
nated,7–10 and hepatitis C virus remains the most
important cause of viral hepatitis in Taiwanese 
hemophiliacs (MC Shen, personal communica-
tion). In addition, PCCs possibly contain activated
factors VII and X; therefore, their use in patients
with hemophilia B may be further complicated
by thrombosis.11
These concerns led to the development of a re-
combinant human FIX (rFIX) product, Benefix®, a
new purified recombinant product, which is free
from the risk of transmitting plasma-derived
human viruses because it is produced in Chinese
hamster ovary cells that have been modified to ex-
press the gene for human FIX without using any
animal or human plasma-derived protein during
the manufacture or formulation of rFIX.12,13 Phar-
macokinetic (PK) studies of rFIX have been done
in patients with severe and moderate hemophilia B
in areas other than Taiwan, and the safety and
efficacy of rFIX in such patients for the treatment of
bleeding episodes have been documented.11,14–17
However, wide patient-related variability in recov-
ery is also noted16 and there is no PK study of rFIX
conducted in Taiwanese patients with hemo-
philia B. Therefore, we performed this PK study
of rFIX in previously treated Taiwanese patients
with hemophilia B and compared the results with
those reported in the literature.
Materials and Methods
Patient population
Nine adult patients with severe (plasma FIX 
activity < 0.01U/mL) and one moderately severe
(plasma FIX activity 0.036 U/mL) hemophilia B
were included in this study during the period from
April to May 2004. The mean age of our patients
was 24.7 ± 8.6 years (mean ± fSD) with a range o
15.5–47.0 years. The mean body weight of our pa-
tients was 66.5 ± 10.8 kg with a range of 50–84 kg.
All of them had been previously treated with
other FIX products. Subjects with currently de-
tectable FIX inhibitor titer (≥ 0.6 Bethesda Unit)
or a history of inhibitors, anaphylaxis to any FIX-
fcontaining product, or clinical manifestations o
liver dysfunction such as serum aspartate amino-
transferase (AST), alanine aminotransferase (ALT)
in excess of 2.5 times the upper limit of the normal
range were excluded. Institutional review board
approved the study in our hospital. Written in-
formed consent was obtained from each individual
prior to enrollment.
Study design
After providing written informed consent, patients
were screened to determine eligibility for partici-
pation in this study. Screening procedures were
performed over a 14–28 day period before the
visit for PK study. Eligible patients received a single
dose of rFIX at the visit for PK study. Multiple
rblood samples were obtained for PK analysis ove
fa period of 72 hours. Laboratory parameters o
blood, including total protein, total bilirubin, AST,
ALT, alkaline phosphatase, blood urea nitrogen,
creatinine, lactate dehydrogenase, glucose, sodium,
gpotassium, and chloride, were checked durin
Kscreening and immediately after the visit for P
study. The patients were followed up in our clinics
in the following 6 months. Any adverse events
were recorded during the study.
PK study
gAll patients received rFIX at a dose of 75 IU/k
intravenously over 10 minutes. All of them were in
no bleeding state and had not used any FIX prod-
ucts during the preceding 4 days. Multiple blood
samples were collected at prior to dosing, 0.25,
X0.5, 1, 2, 3, 6, 12, 24, 48, and 72 hours after rFI
administration for PK analysis. The FIX activity vs.
time curves were obtained and then characterized
to determine the PK parameters. FIX activity was
performed by a one-stage clotting assay15,18–20
using a normal plasma reference standard cali-
brated against a World Health Organization stan-
dard (Dade Behring, Germany).
PK analysis
The FIX activity vs. time curves were used for char-
acterization of PK parameters by standard model-
independent methods. The computer program
used for the determination of PK parameters was
WinNonlin version 3.1 (Pharsight Corp., Mountain
View, CA, USA). The following standard PK para-
meters were determined, which include maximum
concentration (Cmax), area under the curve (AUC),
elimination half-life (t½), total body clearance
(CL), mean residence time (MRT), volume of dis-
tribution at steady-state (Vss), incremental recovery
(K value), and in vivo recovery (%).
Cmax was determined from the observed peak
FIX activity. The areas under the activity vs. time
curves (AUCT) and under the moment curve
(AUMCT) to the last measurable activity (CT) were
calculated by the trapezoidal rule. The terminal-
phase disposition rate constant (λz) was estimated
by regression of the terminal log-linear phase of
the FIX activity vs. time curve. The terminal-phase
disposition half-life (t½) was calculated as:
The AUC from time 0 to infinity (AUCINF) was
estimated as:
Similarly, AUMCT from time 0 to infinity 
(AUMCINF) was estimated as:
where T is the time corresponding to the last
measurable CT. CL and MRT were calculated as:
and
where TI is the duration of infusion. Vss was
calculated as:
The K value, defined as IU/dL of FIX increase in
circulation per IU/kg of rFIX administered, was
estimated using the following formula:
where Ct = 0 is the FIX activity at t = 0 (before 
the start of dose administration). The in vivo re-
kcovery (%) was calculated as the observed pea
activity divided by the plasma activity expected
theoretically. The expected theoretical activity was
calculated by dividing the dose by the patient’s
estimated plasma volume. The blood and plasma
volume were calculated according to Nadler et al21
as the following equations:
Plasma volume (L)
= blood volume × (1 − hemotocrit)
and
Blood volume (L) 
= 0.3669 × [body height (m)]3
+ 0.03219 × body weight (kg) + 0.6041
Statistical analysis
Continuous variables were summarized by de-
scriptive statistics, including mean, range, and
standard deviation (SD). Categorical variables were
presented with the number and percentage in each
category. The comparison between our study and
other groups was examined by t test when both
mean values and SD of variables were available.
A statistically significant difference was defined
as p < 0.05. The computer program used for sta-
tistical analysis was SAS version 8.2 (SAS Institute
Inc., Cary, NC, USA).
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Results
All of the 10 patients in this study were Taiwanese
males and all completed the study. The mean FIX
activity vs. time curve is shown in the Figure, and
PK parameters for these 10 patients were calcu-
lated in the analysis (Table 1). The infusion of
75IU/kg of rFIX in our patients resulted in a mean
FIX activity increase of 1.08 ± 0.27 IU/dL per IU/kg
with a range of 0.75–1.49 IU/dL per IU/kg, corre-
sponding to an in vivo recovery of a mean of
44.0 ± 9.5% with a range of 31.4–60.4%. The mean
elimination half-life was 24.4 ± 6.4 hours with a
range of 14.1–35.3 hours. The mean values of
AUCINF, CL, and Vss were 1363 ± 166 IU × hour/dL,
4.84 ± 1.03 mL/hour/kg, and 144.3 ± 41.8 mL/kg,
respectively.
The rFIX was well tolerated in our patients.
No serious adverse events were related to rFIX.
Two (20%) patients experienced treatment-related
adverse events, including fever and feeling sleepy,
respectively. Both of them resolved spontaneously
without any sequences. There were no withdrawals
due to adverse events. Besides, changes in vital
signs, physical examination, and laboratory pa-
rameters were not clinically significant. There was
no inhibitor to rFIX noted or thrombosis forma-
tion in our patients in the 6 months following
rFIX infusion.
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iF gure. Factor IX (FIX) activity vs. time curve after infusion of 75 IU/kg of
rFIX in our patients. FIX activity is plotted as mean ± standard deviation
(IU/dL) vs. time in hours.
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Discussion
The results of PK study of FIX product are closely
related to its clinical applications and efficacy. 
Low and variable recovery of FIX product has been
noted for a long time,22,23 and remains of con-
siderable importance to treatment practice.24 The
data of previous studies16,23,25–30 suggest that 
patient-specific factors are likely to be, at least in
part, responsible for the wide variability in recov-
Kery. Therefore, it is necessary to perform the P
study of FIX product in a geographic area where
wthis kind of FIX product is regarded as a ne
product to treat patients with hemophilia B.
tThe rFIX has been sporadically used to trea
tour patients with hemophilia B in Taiwan withou
fPharmacokinetic study o  recombinant FIX in Taiwan
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Table 2. Results of pharmacokinetic study in our series and other reports
Parameters
Our study White et al15
Bjorkman &
Roth et al11 Ragni et al14
Ewenstein Poon et al17
(n = 10) (n = 11)
Berntorp31
(n = 56) (n = 24)
et al16 (n = 85, age
(n = 55) (n = 38) > 15 yr)
AUCINF Mean 1363 548 NA NA 641.31 NA NA
(IU × hr/dL) SD 166 92 222.35
Range 1034–1566 363.5–1298.6
p < 0.0001* < 0.0001*
Cmax (IU/dL) Mean 81.7 38.5 NA NA NA NA NA
SD 19.7 13.7
Range 56.2–112
p < 0.0001*
CL (mL/hr/kg) Mean 4.84 7.15 8.4 NA NA NA NA
SD 1.03 1.39
Range 3.3–6.2
p 0.0002*
Vss (mL/kg) Mean 144.3 NA 220 NA NA NA NA
SD 41.8
Range 90.1–216.2
MRT (hr) Mean 30.1 24.9 26 NA NA NA NA
SD 6.6 6.3
Range 19.3–39
p 0.0402*
t½ (hr) Mean 24.4 18.1 20 19.3 21.32 16.8 NA
SD 6.4 5.1 11
Range 14.1–35.3 11.1–36.4 9.9–37.4 10.8–26.1
p 0.011* 0.2108
K value Mean 1.08 0.8 NA 0.75 0.75 0.86 0.84
(IU/dL) SD 0.27 0.30 0.2 0.31 0.21
Range 0.73–1.49 0.34–1.38 0.37–1.23 0.36–1.85
p 0.0175* 0.0002* 0.0222* 0.0006*
In vivo Mean 44.0 37.8 NA 33.7 33.7 34.6 NA
recovery (%) SD 9.5 14.0 8.99 10.3
Range 31.4–60.4 15.3–62.2 15.3–54
p 0.1255 0.0025* 0.0059*
*p < 0.05. AUC = area under the curve; NA = not available; SD = standard deviation; Cmax = maximum concentration; CL = total body clearance; Vss = volume
of distribution at steady-state; MRT = mean residence time; t½ = elimination half-life.
knowing the data about the PK parameters.
Therefore, to ensure the proper dosage of rFIX to
our Taiwanese patients with hemophilia B, we
performed this PK study of rFIX in our patients.
Because hemophilia B is a rare disease, we 
enrolled only 10 patients who were previously
treated with other FIX product in this study. To
obtain accurately measured plasma FIX activity
during the study period, we gave a higher dose 
of rFIX (75 IU/kg) than what is normally used
(50 IU/kg) in other PK studies.11,14–17 The post-
dose blood-sampling interval used in our study was
72 hours; a sampling period that appears to be
sufficient for routine PK study of FIX product.29
When comparing with results of other
groups,11,14–17,31 the mean values of AUCINF, Cmax,
MRT, t½, K value, and in vivo recovery were signif-
icantly higher and the mean value of CL was
significantly lower than other studies (p < 0.05,
Table 2). The higher values of AUCINF and Cmax
were obviously due to the higher dose of rFIX
(75 IU/kg) used in our study. In a PK study of
pdFIX, it has been suggested that FIX recovery was
partly dose-dependent.25 So the higher K value
and in vivo recovery in our study may have resulted
from the higher dose of rFIX used. Besides, the
high value of CL associated with low in vivo
recovery of rFIX is well known.23 The CL in our
study is obviously lower as compared with other
reports,15,23 which results in longer activity half-life,
higher K value, and in vivo recovery in our study
(Table 2). In a large PK study of rFIX in 55 pa-
tients aged 4–56 years and weighing 18–133kg,32
both CL and Vss were correlated with body weight
linearly, consequently increasing during child-
hood and adolescence but remaining fairly con-
stant during adulthood. MRT in that study showed
no regression with either body weight or age, but 
K value increased with age and body weight. The
patients in our study were all adults and none
were overweight. The difference of PK parameters
between our study and other reports may be due
to ethnic factors, different demographic character-
istics of the patients, the limited patient number,
or the higher single dose of rFIX (75 IU/kg) used
in our study.
The Vss of rFIX is larger than estimated plasma
volume in our PK study (Table 1). rFIX has a
rmolecular weight about 66 kDa which is simila
to albumin (69 kDa). Theoretically, it should be
mainly confined to the intravascular space.
However, FIX can bind to the vascular endothe-
lium rapidly and reversibly, with a half-maximal
binding concentration comparable to its normal
concentration in plasma, which may create a
transient “marginal pool”.33,34 This may be the
reason for why the volume of distribution of XrFI
was larger than the estimated plasma volume in
our PK study.
The results of our PK study of rFIX were com-
parable to those reported in the current literature
(Table 2). Although our results were similar to a
cross-over PK study of high-purified FIX,35 the K
value and in vivo recovery of rFIX in our study were
rstill significantly lower than that of pdFIX in othe
studies.15–17 The reasons for this phenomenon
have been discussed.11,16 The differences in the
post-translational modification between rFIX and
pdFIX were believed to be responsible for the
lower recovery observed in rFIX, although the
under-carboxylation of rFIX has no influence on
its specific coagulant activity.36,37
In conclusion, the results of PK study of rFIX in
previously treated Taiwanese patients with hemo-
philia B are comparable to the reported results
tfrom other related studies conducted in differen
Xgeographical areas. It could be expected that rFI
would be clinically safe and effective in the treat-
ment of Taiwanese patients with hemophilia B.
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